Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients

• Hauptverfasser: Adi Horesh (Verfasst von), Rena Pollack (Verfasst von), Hovav Nechushtan (Verfasst von), Rivka Dresner-Pollak (Verfasst von), Tzahi Neuman (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 express...